<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01202474</url>
  </required_header>
  <id_info>
    <org_study_id>APIDR_L_04884</org_study_id>
    <secondary_id>U1111-1116-8645</secondary_id>
    <nct_id>NCT01202474</nct_id>
  </id_info>
  <brief_title>Apidra Children &amp; Adolescents Study</brief_title>
  <official_title>A Study of Effectiveness and Safety of Apidra in Combination With Lantus Therapy in Basal-bolus Insulin Regimen in Inadequately Controlled Children and Adolescents With Type 1 Diabetes in the Russian Federation.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      Evaluate the percentage of patients achieving glycosylated hemoglobin (HbA1c) level &lt; 8% (in&#xD;
      patients of 6-12 years old) and HbA1c level &lt; 7.5% (in patients of 13-17 year old) at 6 and&#xD;
      12 months of treatment&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      Change in HbA1c level at 6 and 12 months of treatment Monthly rate of hypoglycaemia/per&#xD;
      patient from the baseline to the end of the study Change in daily dose of glargine and&#xD;
      glulisine at 6 and 12 months of treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">October 2012</completion_date>
  <primary_completion_date type="Actual">October 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients achieving HbA1c level &lt; 8% (in patients 6-12 year-old) and HbA1c level &lt; 7.5 % (in patients 13-17 year-old)</measure>
    <time_frame>at 6 and 12 months of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c plasma level</measure>
    <time_frame>at 6 and 12 months of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monthly rate of hypoglycaemia</measure>
    <time_frame>from baseline to 12 months of treatment (study cut off)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in daily dose of glargine and glulisine</measure>
    <time_frame>at 6 and 12 months of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <arm_group>
    <arm_group_label>insulin glulisine and insulin glargine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>insulin glulisine and insulin glargine basal/bolus regimen in accordance with the summary of product characteristics and titrated to Plasma glucose target as defined by American Diabetes Association (ADA) recommendations age-specific goals (12)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLULISINE</intervention_name>
    <description>Pharmaceutical form: solution for injection Route of administration: subcutaneous Dose regimen: once a day</description>
    <arm_group_label>insulin glulisine and insulin glargine</arm_group_label>
    <other_name>Apidra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>INSULIN GLARGINE</intervention_name>
    <description>Pharmaceutical form:solution for injection Route of administration: subcutaneous Dose regimen: 0-15 minutes before meal or within 20 minutes from the start of meal according to prandial plasma glucose values</description>
    <arm_group_label>insulin glulisine and insulin glargine</arm_group_label>
    <other_name>Lantus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
          -  ChildrenAdolescents with Type 1 diabetes Mellitus l(T1DM) onger than 1 year duration&#xD;
&#xD;
          -  Age 6 -17 y.o.&#xD;
&#xD;
          -  With 8%&lt;HbA1c &lt;10%&#xD;
&#xD;
          -  Treated with insulin glargine and any rapid insulin&#xD;
&#xD;
          -  Ability to perform a self blood-glucose monitoring (SBGM)&#xD;
&#xD;
          -  Signed Informed consent.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Diabetes Mellitus type 2&#xD;
&#xD;
          -  ChildrenAdolescents with Type 1 diabetes Mellitus previously treated with Apidra&#xD;
&#xD;
          -  Hypersensitivity to Insulin glulisine&#xD;
&#xD;
          -  Pregnant or lactation women&#xD;
&#xD;
          -  Gestational diabetes mellitus&#xD;
&#xD;
          -  Treatment with systemic corticosteroids in the 1 month prior to study entry&#xD;
&#xD;
          -  T1DM complications: such as already existing active proliferative diabetic&#xD;
             retinopathy, as defined by the application of photocoagulation or surgery, in the 6&#xD;
             months before study entry or any other unstable (rapidly progressing) retinopathy that&#xD;
             may require photocoagulation or surgery during the study.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Administrative office</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <study_first_submitted>September 14, 2010</study_first_submitted>
  <study_first_submitted_qc>September 14, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2010</study_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin glulisine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

